Figure 3.

Downregulation of miR-515–3p expression by PACT leads to increased chemosensitivity of MOC. A, Heat map showing the 11 most upregulated mature miRNA levels under PRKRA-silenced conditions assessed using miRNA array data. B, Expression levels for significantly altered mature miRNAs in PRKRA-silenced in RMUG-L-ip1 cells. C, Mature miR-515–3p expression levels in RMUG-S-ip1 cells transfected with a plasmid containing FLAG, wild-type PACT, or PACT mDR3. D, RNA immunoprecipitation (RIP) analysis of miR-515–3p expression in RMUG-S-ip1 cells transfected with control siRNA, siPRKRA, empty vector, wild-type PACT plasmid or PACT mDR3 plasmid. E, Cell viability assay for PRKRA-silenced RMUG-L-ip1 cells transfected with a wild-type PACT-containing plasmid or mutant plasmid. The cells were treated with oxaliplatin. F, Cell viability assay of PRKRA-silenced RMUG-L-ip1 cells transfected with a miR-515–3p inhibitor or control antisense inhibitor. The cells were treated with oxaliplatin. G, Mature miR-515–3p and PRKRA expression levels in tumors obtained from RMUG-L-ip1 mouse models which treated with control siRNA, control siRNA plus oxaliplatin, siPRKRA, or siPRKRA plus oxaliplatin. Data are presented as means ± standard error of the mean for at least three experimental groups. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (Student t-test).